TME Pharma launched today a €2.6 million financing via public offer reserved for its shareholders on the record date of December 11, 2024 who can subscribe from today through December 18,2024. This public offer is 100% guaranteed by a group of existing shareholders of the company and a corporate partner. Follow for more details on the Public Offer: https://lnkd.in/dfCpE4ap
TME Pharma
Arzneimittelherstellung
Developing novel therapies for treatment of the most aggressive cancers by acting on the tumor microenvironment (TME)
Info
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.
- Website
-
https://www.tmepharma.com
Externer Link zu TME Pharma
- Branche
- Arzneimittelherstellung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Berlin
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1998
Orte
-
Primär
Wegbeschreibung
Max-Dohrn-Str. 8-10
Berlin, 10589, DE
Beschäftigte von TME Pharma
Updates
-
Visit the TME Pharma investors page for the latest analyst report by invest securities. https://is.gd/cYSSHI
-
-
TME Pharma intends to launch a €2.6M public offer on December 12, reserved for its shareholders. This financing will extend our financial visibility from January into June 2025, enabling us to complete strategic transactions for NOX-A12 and NOX-E36. For key information, read the announcement, and stay tuned for more details to follow. https://is.gd/YZcy9K
-
-
A poster presentation featuring the NOX-A12 data from preclinical studies performed at the US National Cancer Institute (NCI) Cancer Institute has been presented at the 2024 SNO Annual Meeting held in Huston, Texas. The presentation highlights synergistic effect of combining CXCL12 inhibition with immune checkpoint inhibition in brain cancer models inducing a favorable tumor microenvironment (TME) for anti-tumor immune responses. The study results support the different combination strategies pursued by TME Pharma in Brain and Pancreas cancer. Read More: https://is.gd/YZcy9K
-
-
We’re excited to announce that our team is attending the **2024 SNO Annual Meeting** in Houston, TX, from **November 21–24**! We look forward to connecting with clinicians, scientists, and peers who are deeply committed to advancing **Glioblastoma research**. If you’re attending, we’d love to meet you! Stop by our **Exhibition Booth #412** to learn more about our work and explore opportunities to collaborate. #Glioblastoma #SNO2024 #InnovationInOncology #Collaboration
-
-
Visit the TME Pharma Investors page for the latest information including the new In Extenso Finance Analyst Report. https://is.gd/cYSSHI
-
-
Visit the TME Pharma Investors page for the latest information including the new In Extenso Finance Analyst Report. Read Here: https://is.gd/cYSSHI
-
-
We are excited to announce that TME Pharma has been awarded a grant of €2.4 million from the KMU-innovativ funding program, managed by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF). This non-dilutive funding will support TME Pharma’s upcoming Phase 2 randomized controlled study, which will evaluate its lead asset, the CXCL12 inhibitor NOX-A12, for the treatment of aggressive adult brain cancer, glioblastoma. Read the PR now: https://is.gd/YZcy9K
-
-
Congratulations to Dr. Frank A. Giordano and the entire research team on these exciting advancements in glioblastoma treatment. Your dedication to exploring innovative approaches like dual CXCL12 and VEGF inhibition is remarkable. We're honored to be part of this critical work and we look forward to seeing how this research potentially transforms treatment paradigms. Thank you for your unwavering commitment to improving outcomes for glioblastoma patients.
#Glioblastoma remains one of the most challenging cancers to treat. Our latest research focuses on blocking #CXCL12 and #VEGF. By inhibiting both, we’re seeing promising advancements in improving patient outcomes and offering new hope in a space where effective treatments are critically needed. It’s incredible to be part of a fantastic team pushing the boundaries in brain cancer care: Thank you Julian Layer Michael Hölzel Nils Nicolay Clemens Seidel Ghazaleh Tabatabai Sonia Leonardelli, PhD Elena Sperk Michael Platten Sotirios Bisdas Sied Kebir and TME Pharma for all your support and your continuous trust in us.
-
-
TME Pharma is delighted to announce the addition of Alexandra (Sandra) Glucksmann to our Supervisory Board. With over 30 years of leadership experience in the biotech industry, Dr. Glucksmann is a distinguished US biopharma executive and accomplished scientist. She currently serves as the President and CEO Sensorium Therapeutics, a private biotech company specializing in CNS disorders. Her expertise will be invaluable as we navigate key milestones ahead. For more details, please visit our website.https://is.gd/H30aKU
-